Issued 2026-09-16 at $68.51 · now $68.51 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, VEON has typically landed between $54.24 and $86.36 — a range of −20.8% to +26.1% from the issuance price $68.51.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
5,003 overlapping 1 month windows · 2006-09-26 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($68.51) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where VEON has typically landed a month from the 2026-09-16 close of $68.51 — the range is history, not a prediction.
- now $68.51 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $69.19 (+1.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $63.61–$74.76
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $54.24–$86.36
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-02-01 | −81.7% | −81.7% | +8.5% |
| 2022-02-10 | −76.3% | −82.9% | +1.3% |
| 2022-02-09 | −75.8% | −83.0% | +0.7% |
| 3 best | |||
| 2022-03-03 | +180.8% | +0.0% | +180.8% |
| 2022-10-28 | +100.0% | +0.0% | +103.3% |
| 2022-10-26 | +96.8% | −3.2% | +96.8% |
5,003 overlapping windows · 2006-09-26 – 2026-09-16 · not cherry-picked
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Fabela Augie K II | director | Purchase | 5,000 @ $56.02 | $280K | +5.5% of holding | +14.5% | not yet — horizon still open | 96,000 | Form 4 · filed 3 days after the trade |
| 2026-08-06 | Fabela Augie K II | director | Purchase | 13,826 @ $56.05 | $775K | +17.9% of holding | +14.7% | not yet — horizon still open | 91,000 | Form 4 · filed 4 days after the trade |
| 2026-08-06 | Fabela Augie K II | director | Purchase | 1,174 @ $55.30 | $65K | +1.5% of holding | +14.7% | not yet — horizon still open | 77,174 | Form 4 · filed 4 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
1 award / exercise / gift record — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-07 | Pompeo Michael | director | Award / grant | 38,205 | 186,435 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.